Rating Change
B of A Securities reiterated its Neutral rating on Candel Therapeutics, Inc. (NASDAQ:CADL) on August 14, 2026.
reiterateNASDAQ:CADL
B of A Securities Reiterates Neutral Rating on Candel Therapeutics, Inc. (CADL)
B of A Securities reiterated its Neutral rating on Candel Therapeutics, Inc. (NASDAQ:CADL) on August 14, 2026.
At publication ·
What changed
Candel Therapeutics, Inc. (NASDAQ:CADL) · reiterate
- Firm
- B of A Securities
- Rating
- Neutral to Neutral
- Price at event
- $11.72
- Market capitalization
- $355.8M
At a glance
Key takeaways
- Bank of America Securities reiterated a Neutral rating on Candel Therapeutics (CADL) on August 14, 2026, while the stock trades at $11.72 with a market capitalization of $355.8 million.
Market Context
Candel Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $11.72 with a market capitalization of $355.8M.
Analyst coverage from B of A Securities provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Candel Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Candel Therapeutics, Inc.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 14, 2026 | B of A Securities | Neutral | N/A |
| Aug 13, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jul 13, 2026 | Stifel | Buy | N/A |
| Apr 20, 2026 | Cantor Fitzgerald | Overweight | N/A |
| Mar 18, 2026 | Citigroup | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View CADL Stock Page
Frequently Asked Questions
What does the Neutral rating mean for CADL?
A rating of Neutral from B of A Securities reflects the analyst's outlook on Candel Therapeutics, Inc. (NASDAQ:CADL). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the CADL forecast page.